Trial Profile
Phase III trial of Etirinotecan pegol [NKTR-102] in patients with ovarian cancer.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2011
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Nektar Therapeutics
- 07 Jul 2010 New trial record